News and Announcements
How To Find The Perfect Investor For Your Capital Raise
- Published December 20, 2022 2:31AM UTC
- Publisher Leila Oliveira
- Categories Capital Raising Tips
“I’m in conversations with VCs”
Good! But does your startup fit their criteria?
Typically VCs invest in 1-2% of companies they have initial conversations with.
The 1% is more likely to be companies with:
– Exponential growth metrics
– Big market adoption
– First in their sector
– Well known management board
If your company isn’t there yet but needs to raise capital, consider other groups such as HNW and family offices.
Which group do you think would be the best fit for your current round?
[ Source: Gompra, Gomail, Kaplan, Strebulaev – How do Venture Capitalist make decisions report]
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
